Analogs of the sea anemone potassium channel blocker ShK for the treatment of autoimmune diseases

Inflammation and Allergy - Drug Targets

Volumn 10, Issue 5, 2011, Pages 313-321

  Beeton, Christine ^a   Pennington, Michael W ^b   Norton, Raymond S ^c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Peptides International   (United States)

^c MONASH UNIVERSITY   (Australia)

Author keywords

Autoimmunity; Immunomodulator; Kv1.3 channel; Lymphocyte; Venom peptide

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CHEMOKINE RECEPTOR CCR7; D ALLO SHK; POLYPEPTIDE; POTASSIUM CHANNEL KV1.3; PROTEINASE; SHK; SHK 170; SHK 186; SHK 192; SHK DAP 22; UNCLASSIFIED DRUG;

ARTHRITIS; ARTICLE; AUTOIMMUNE DISEASE; CENTRAL AMERICA; CONCENTRATION (PARAMETERS); DELAYED HYPERSENSITIVITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG SELECTIVITY; DRUG STABILITY; HUMAN; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; MEMORY T LYMPHOCYTE; MULTIPLE SCLEROSIS; MUTAGENESIS; NONHUMAN; PROTEIN BINDING; PROTEIN STRUCTURE; RHEUMATOID ARTHRITIS; SEA ANEMONE; SKIN ALLERGY; STICHODACTYLA HELIANTHUS;

EID: 80052852577     PISSN: 18715281     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152811797200641     Document Type: Article

References (33)

1. Hille, B. Ionic channels of excitable membranes. Sinauer Associates: Sunderland, Mass., 2001; p 426.
2. Chandy, K. G.; Wulff, H.; Beeton, C.; Pennington, M. W.; Gutman, G. A.; Cahalan, M. D., K+ channels as targets for specific immunomodulation. Trends Pharmacol. Sci., 2004, 25, 280-289.
3. Sallusto, F.; Lenig, D.; Forster, R.; Lipp, M.; Lanzavecchia, A., Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature, 1999, 401(6754), 708-712.
4. + channel in effector memory T cells as new target for MS. J. Clin. Invest., 2003, 111, (11), 1703-1713.
5. Beeton, C.; Wulff, H.; Standifer, N. E.; Azam, P.; Mullen, K. M.; Pennington, P. W.; Kolski-Andreaco, A.; Wei, E.; Grino, A.; Counts, D. R.; Wang, P. H.; LeeHealey, C. J.; Andrews, B. S.; Sankaranarayanan, A.; Homerick, D.; Roeck, W. W.; Tehranzadeh, J.; Stanhope, K. L.; Zimin, P.; Havel, P. J.; Griffey, S.; Knaus, H. G.; Nepom, G. T.; Gutman, G. A.; Calabresi, P. A.; Chandy, K. G., Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc. Natl. Acad. Sci. U S A., 2006, 103, 17414-17419.
6. Castañeda, O.; Sotolongo, V.; Amor, A. M.; Stöcklin, R.; Anderson, A. J.; Harvey, A. L.; Engström, Å.; Wernstedt, C.; Karlsson, E., Characterization of a potassium channel toxin from the Caribbean Sea anemone Stichodactyla helianthus. Toxicon., 1995, 33, 603-613.
7. Pennington, M.; Byrnes, M.; Zaydenberg, I.; Khaytin, I.; de Chastonay, J.; Krafte, D.; Hill, R.; Mahnir, V.; Volberg, W.; Gorczyca, W.; Kem, W., Chemical synthesis and characterization of ShK toxin: a potent potassium channel inhibitor from a sea anemone. Int. J. Pept. Protein Res., 1995, 346, 354-358.
8. Pohl, J.; Hubalek, F.; Byrnes, M. E.; Nielsen, K. R.; Woods, A.; Pennington, M. W., Assignment of the three disulfide bonds in ShK toxin: A potent potassium channel inhibitor from the sea anemone Stichodactyla helianthus. Lett. Peptide Sci., 1994, 1, 291-297.
9. Schweitz, H.; Bruhn, T.; Guillemare, E.; Moinier, D.; Lancelin, J. M.; Beress, L.; Lazdunski, M., Kalicludines and kaliseptine. J. Biol. Chem., 1995, 270, 25121-25126.
10. Cotton, J.; Crest, M.; Bouet, F.; Alessandri, N.; Gola, M.; Forest, E.; Karlsson, E.; Castaneda, O.; Harvey, A. L.; Vita, C.; Menez, A., A potassium-channel toxin from the sea anemone Bunodosoma granulifera, an inhibitor for Kv1 channels. Revision of the amino acid sequence, disulfide-bridge assignment, chemical synthesis, and biological activity. Eur. J. Biochem., 1997, 244, 192-202.
11. + channels characterized from Androctonus mauretanicus mauretanicus venom. J. Biol. Chem., 1992, 267, 1640-1647.
12. Garcia-Calvo, M.; Leonard, R. J.; Novick, J.; Stevens, S. P.; Schmalhofer, W.; Kaczorowski, G. J.; Garcia, M. L., Purification, characterization, and biosynthesis of margatoxin, a component of Centruroides margaritatus venom that selectively inhibits voltagedependent potassium channels. J. Biol. Chem., 1993, 268(25), 18866-18874.
13. + channel blocker peptide, purified from the venom of the scorpion Centruroides noxius Hoffmann. Carlsberg Res. Commun., 1982, 47, 285-289.
14. Tudor, J. E.; Pallaghy, P. K.; Pennington, M. W.; Norton, R. S., Solution structure of ShK toxin, a novel potassium channel inhibitor from a sea anemone. Nat. Struct. Biol., 1996, 3(4), 317-320.
15. Pennington, M.; Mahnir, V.; Krafte, D.; Zaydenberg, I.; Byrnes, M.; Khaytin, I.; Crowley, K.; Kem, W., Identification of three separate binding sites on ShK toxin, a potent inhibitor of voltagedependent potassium channels in human T-lymphocytes and rat brain. Biochem. Biophys. Res. Commun., 1996, 219, 696-701.
16. Kalman, K.; Pennington, M. W.; Lanigan, M. D.; Nguyen, A.; Rauer, H.; Mahnir, V.; Paschetto, K.; Kem, W. R.; Grissmer, S.; Gutman, G. A.; Christian, E. P.; Cahalan, M. D.; Norton, R. S.; Chandy, K. G., ShK-Dap22, a potent Kv1.3-specific immunosuppressive polypeptide. J. Biol. Chem. 1998, 273(49), 32697-32707.
17. Rauer, H.; Pennington, M.; Cahalan, M.; Chandy, K. G., Structural conservation of the pores of calcium-activated and voltage-gated potassium channels determined by a sea anemone toxin. J. Biol. Chem., 1999, 274(31), 21885-21892.
18. Tudor, J. E.; Pennington, M. W.; Norton, R. S., Ionisation behaviour and solution properties of the potassium-channel blocker ShK toxin. Eur. J. Biochem., 1998, 251(1/2), 133-141.
19. Lanigan, M. D.; Kalman, K.; Lefievre, Y.; Pennington, M. W.; Chandy, K. G.; Norton, R. S., Mutating a critical lysine in ShK toxin alters its binding configuration in the pore-vestibule region of the voltage-gated potassium channel, Kv1.3. Biochemistry, 2002, 41, 11963-11971.
20. Pennington, M. W.; Beeton, C.; Galea, C. A.; Smith, B. J.; Chi, V.; Monaghan, K. P.; Garcia, A.; Rangaraju, S.; Giuffrida, A.; Plank, D.; Crossley, G.; Nugent, D.; Khaytin, I.; LeFievre, Y.; Peshenko, I.; Dixon, C.; Chauhan, S.; Orzel, A.; Inoue, T.; Hu, X.; Moore, R. V.; Norton, R. S.; Chandy, K. G., Engineering a stable and selective peptide blocker of the Kv1.3 channel in T lymphocytes. Mol. Pharmacol., 2009, 75, 762-773.
21. Beeton, C.; Pennington, M. W.; Wulff, H.; Singh, S.; Nugent, D.; Crossley, G.; Khaytin, I.; Calabresi, P. A.; Chen, C.-Y.; Gutman, G. A.; Chandy, K. G., Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases. Mol. Pharmacol., 2005, 67, 1369-1381.
22. Beeton, C.; Smith, B. J.; Sabo, J. K.; Crossley, G.; Nugent, D.; Khaytin, I.; Chi, V.; Chandy, K. G.; Pennington, M. W.; Norton, R. S., The D-diastereoisomer of ShK toxin selectively blocks voltagegated K+ channels and inhibits T lymphocyte proliferation. J. Biol. Chem., 2008, 283, 988-997.
23. Beeton, C.; Wulff, H.; Singh, S.; Botsko, S.; Crossley, G.; Gutman, G. A.; Cahalan, M. D.; Pennington, M. W.; Chandy, K. G., A novel fluorescent toxin to detect and investigate Kv1.3 channel upregulation in chronically activated T lymphocytes. J. Biol. Chem., 2003, 278(11), 9928-9937.
24. Matheu, M. P.; Beeton, C.; Garcia, A.; Chi, V.; Rangaraju, S.; Safrina, O.; Monaghan, K.; Uemura, M. I.; Li, D.; Pal, S.; de la Maza, L. M.; Monuki, E.; Flugel, A.; Pennington, M. W.; Parker, I.; Chandy, K. G.; Cahalan, M. D., In situ imaging of effector memory T cells during DTH and suppression by Kv1.3 channel block. Immunity 2008, 29, 602-614.
25. Beeton, C.; Wulff, H.; Barbaria, J.; Clot-Faybesse, O.; Pennington, M. W.; Bernard, D.; Cahalan, M. D.; Chandy, K. G.; Beraud, E., Selective blockade of T lymphocyte K+ channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis. Proc. Natl. Acad. Sci. USA., 2001, 98, 13942-13947.
26. Yan, L.; Herrington, J.; Goldberg, E.; Dulski, P. M.; Bugianesi, R. M.; Slaughter, R. S.; Banerjee, P.; Brochu, R. M.; Priest, B. T.; Kaczorowski, G. J.; Rudy, B.; Garcia, M. L., Stichodactyla helianthus peptide, a pharmacological tool for studying Kv3.2 channels. Mol. Pharmacol., 2005, 67, 1513-1521.
27. Matsueda, G. R.; Steward, J. M., A p-methylbenzhydrylamine resin for improved solid-phase synthesis of peptide amides. Peptides 1981, 2, 45-50.
28. Beeton, C.; Chandy, K. G., Potassium channels, memory T cells and multiple sclerosis. Neuroscientist 2005, 11, 550-562.
29. + channels improves experimental autoimmune encephalomyelitis and inhibits T cell activation. J. Immunol., 2001, 166, 936-944.
30. Chandy, K. G.; DeCoursey, T. E.; Cahalan, M. D.; McLaughlin, C.; Gupta, S., Voltage-gated potassium channels are required for human T lymphocyte activation. J. Exp. Med., 1984, 160(2), 369-385.
31. Koo, G. C.; Blake, J. T.; Shah, K.; Staruch, M. J.; Dumont, F.; Wunderler, D.; Sanchez, M.; McManus, O. B.; Sirotina-Meisher, A.; Fischer, P.; Boltz, R. C.; Goetz, M. A.; Baker, R.; Bao, J.; Kayser, F.; Rupprecht, K. M.; Parsons, W. H.; Tong, X. C.; Ita, I. E.; Pivnichny, J.; Vincent, S.; Cunningham, P.; Hora, D. J.; Feeney, W.; Kaczorowski, G., et al., Correolide and derivatives are novel immunosuppressants blocking the lymphocyte Kv1.3 potassium channels. Cell. Immunol., 1999, 197, 99-107.
32. Azam, P.; Sankaranarayanan, A.; Homerick, D.; Griffey, S.; Wulff, H., Targeting effector memory T cells with the small molecule Kv1.3 blocker PAP-1 suppresses allergic contact dermatitis. J. Invest. Dermatol., 2007, 127, 1419-1429.
33. Desir, G. V., Kv1.3 potassium channel blockade as an approach to insulin resistance. Expert Opin. Ther. Targets, 2005, 9, 571-579.